TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Phase 3 Study Investigating the Efficacy and Safety of TAVT-45 (Abiraterone Acetate) Granules for Oral Suspension (Novel Abiraterone Acetate Formulation) Relative to a Reference Abiraterone Acetate Formulation in Patients With mCSPC & mCRPC
Sponsor: Tavanta Therapeutics
Listed as NCT04887506, this PHASE3 trial focuses on Metastatic Castration-resistant Prostate Cancer and Metastatic Castration-sensitive Prostate Cancer and remains completed. Sponsored by Tavanta Therapeutics, it has been updated 13 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Feb 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
First recorded
May 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tavanta Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .